Register an account to search through 14,000+ stocks! 

Ad

DLPA – Dr. Lal PathLabs Ltd

Ad

Compliant

★★★★★

Industry: Healthcare Facilities & Services | NSE

Dr. Lal PathLabs Ltd is Shariah compliant. The company passes all five major Shariah standards.

Market cap: 2,042 MRev. Growth: 64.21%

AAOIFI ✓

Debt/MC3.44%
Non-Compliant Assets/MC0.81%

S&P ✓

Debt/36 mo MC2.79%
Cash/36 mo MC3.24%
AR/36 mo MC%

DJIM ✓

Debt/24 mo MC2.33%
Cash/24 mo MC2.7%
AR/24 mo MC%

FTSE ✓

Debt/Assets22.64%
Cash/Assets26.25%
Cash&AR/Assets26.25%

MSCI ✓

Debt/Assets22.64%
Cash/Assets26.25%
Cash&AR/Assets26.25%

Recommendation Rating

2.89

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 34.89

Low: 24.42

High: 64.25

Total Analysts: 18


Dr. Lal PathLabs Limited is engaged in providing diagnostic and related healthcare tests and services. The Company is also engaged in running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, and other pathological and radiological investigations. The Company offers a range of tests by condition, which includes allergy, diabetes, health checkups, viral infections, fever, heart diseases, hypertension, cancer, abortions, anemia, arthritis, breast cancer, diphtheria, disorder of the liver, disorders of bone, drugs of abuse, infertility, lymphoma, tuberculosis, ovarian cancer, osteoporosis, multiple sclerosis, muscular disorder and viral infections. The Company’s subsidiaries include Paliwal Diagnostics Private Limited, Paliwal Medicare Private Limited, Dr. Lal PathLabs Nepal Private Limited, Dr. Lal PathLabs Bangladesh Pvt. Ltd. and Dr. Lal Ventures Private Limited.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.

To understand how the screening is done, please read the Shariah Screening Methodology page.

Ad

Responses